CBD Oil Dosage For Seizures

CBDISTILLERY

Buy CBD Oil Online

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study Of the 132 patients enrolled, 77% remained in the study at 24 months. Children with drug-resistant epilepsy may find relief with the help of medical cannabis oil that contains both CBD and lose dose THC. The oil, which contains 95% CBD and 5% THC, can reduce or prevent epileptic seizures in those with epileptic encephalopathy. Low Dose of CBD Liquid Eases Epilepsy Seizures: Study

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study

Of the 132 patients enrolled, 77% remained in the study at 24 months.

CBD was associated with sustained reduction in seizure frequency and severity at 24 months.

Addition of CBD resulted in a sustained decrease in the adverse events profile.

Abstract

The objective of this study was to characterize the changes in adverse events, seizure severity, and frequency in response to a pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex®) in a large, prospective, single-center, open-label study. We initiated CBD in 72 children and 60 adults with treatment-resistant epilepsy (TRE) at 5 mg/kg/day and titrated it up to a maximum dosage of 50 mg/kg/day. At each visit, we monitored treatment adverse events with the adverse events profile (AEP), seizure severity using the Chalfont Seizure Severity Scale (CSSS), and seizure frequency (SF) using seizure calendars. We analyzed data for the enrollment and visits at 12, 24, and 48 weeks. We recorded AEP, CSSS, and SF at each follow-up visit for the weeks preceding the visit (seizures were averaged over 2-week periods). Of the 139 study participants in this ongoing study, at the time of analysis, 132 had 12-week, 88 had 24-week, and 61 had 48-week data. Study retention was 77% at one year. There were no significant differences between participants who contributed all 4 data points and those who contributed 2 or 3 data points in baseline demographic and AEP/SF/CSSS measures. For all participants, AEP decreased between CBD initiation and the 12-week visit (40.8 vs. 33.2; p < 0.0001) with stable AEP scores thereafter (all p ≥ 0.14). Chalfont Seizure Severity Scale scores were 80.7 at baseline, decreasing to 39.2 at 12 weeks (p < 0.0001) and stable CSSS thereafter (all p ≥ 0.19). Bi-weekly SF decreased from a mean of 144.4 at entry to 52.2 at 12 weeks (p = 0.01) and remained stable thereafter (all p ≥ 0.65). Analyses of the pediatric and adult subgroups revealed similar patterns. Most patients were treated with dosages of CBD between 20 and 30 mg/kg/day. For the first time, this prospective, open-label safety study of CBD in TRE provides evidence for significant improvements in AEP, CSSS, and SF at 12 weeks that are sustained over the 48-week duration of treatment.

Cannabis dosage studied to reduce seizures in children with severe epilepsy

Summary: Children with drug-resistant epilepsy may find relief with the help of medical cannabis oil that contains both CBD and lose dose THC. The oil, which contains 95% CBD and 5% THC, can reduce or prevent epileptic seizures in those with epileptic encephalopathy.

Source: University of Saskatchewan

Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a study by the University of Saskatchewan (USask), Canada has found.

See also  CBD Hemp Oil Pancreatic Cancer

Children with severe epilepsy also experienced improvements in their quality of life after taking low doses of the medicinal cannabis oil, according to research published in Frontiers in Neurology.

The study tested the effects of medicinal cannabis oil with 95 percent CBD, a chemical which does not create a high, and 5 percent THC, a substance which can be intoxicating in large enough doses.

Studying an evidence-based scientifically guided dosage regimen, the research team found no evidence of THC intoxication when using CBD-enriched whole plant extracts.

“What makes these results really exciting is it opens up as a treatment option for kids who have failed to respond to traditional medications,” said Dr. Richard Huntsman (M.D), a pediatric neurologist who led the study.

Three of the seven children in the USask study–mainly funded by Saskatchewan’s Jim Pattison Children’s Hospital Foundation–stopped having seizures altogether.

“Some of the improvements in quality of life were really dramatic with some of the children having huge improvements in their ability to communicate with their families. Some of these children started to talk or crawl for the first time. They became more interactive with their families and loved ones,” said Dr. Huntsman.

Several studies have shown that cannabis products containing CBD can be effective in helping to control seizures in children with epileptic encephalopathy, a severe form of epilepsy which begins in childhood. Despite this, many children cannot access these products because there is very little guidance for physicians on which doses to use and some health-care providers are concerned about possible intoxication from THC.

This research found that most of the children had a reduction in seizures with a twice-daily dose of CBD totaling 5-6 milligrams of cannabis extract per kilogram of weight (mg/kg) per day. By the time a CBD dose of 10-12 mg/kg per day was achieved, all children experienced a reduction in their seizures, most by more than 50 percent.

“What is really important is that we have been able to dispel in a scientific manner some of the concerns about how to dose these products and the possibility of them causing a ‘high’ in these children. We did this by slowly increasing the dose of cannabis extract in a very tightly regulated manner. We watched the children very closely for side effects and measured blood levels of CBD and THC,” said Dr. Huntsman,

The children had drug-resistant epilepsy, failing to respond to at least two forms of anti-convulsant medication. They had been prescribed several anti-convulsant medications yet continued to have seizures, with one child experiencing 1,223 in the month leading up to the study.

“We are very proud to support this important pediatric research, which is making such a difference in the lives of children who have severe epilepsy,” said Brynn Boback-Lane, President and CEO of Jim Pattison Children’s Hospital Foundation.

“This groundbreaking study is giving hope and improved health outcomes. It is heartening to have donors that see the value of such important work.”

Allyssa Sanderson’s eight-year-old son Ben from Prince Albert, Sask. was one of the participants in the study. Ben was born without complications but later developed infantile spasms. When Ben was two, he was diagnosed with Lennox-Gastaut syndrome, a severe form of epilepsy.

See also  Talyoni CBD Oil Reviews

Studying an evidence-based scientifically guided dosage regimen, the research team found no evidence of THC intoxication when using CBD-enriched whole plant extracts. The image is in the public domain.

Despite trying multiple medications and treatments, Ben’s seizures were unpredictable. He was seizure-free on some days, but on others had 150 seizures a day.

“Ben was very lethargic and would just lay there and have seizures all day. He wasn’t active and didn’t even want to eat. His eyes looked dull, and he didn’t focus on anything. He really looked lifeless,” Allyssa explained. “I knew this trial was a last resort for my son.”

Once Ben started taking CBD, he began showing improvements in his seizure frequency and then became seizure-free during the study.

“I was seeing the change in Ben every single day. I was thankful as I watched his little personality come out. He was back to his silly self that I hadn’t seen in years. He was stronger. I believe this research is one of the greatest things to happen for kids with epilepsy,” Allyssa said.

Low Dose of CBD Liquid Eases Epilepsy Seizures: Study

HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.

  1. All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
  2. Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
  3. Each article includes a link or reference to the original source.
  4. Any known potential conflicts of interest associated with a study or source are made clear to the reader.

HealthDay Editorial Commitment

HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.

WEDNESDAY, May 16, 2018 (HealthDay News) — Less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol, a new clinical trial suggests.

Patients taking a 10-milligram (mg) daily dose of pharmaceutical grade cannabidiol (CBD) experienced nearly as great a reduction in seizures as patients on 20 mg, and with fewer side effects, said lead researcher Dr. Orrin Devinsky. He is director of NYU Langone’s Comprehensive Epilepsy Center in New York City.

This is the third clinical trial to show that the cannabidiol medication Epidiolex is useful in treating two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, Devinsky said.

An advisory panel for the U.S. Food and Drug Administration unanimously recommended in April that Epidiolex be approved for use in the United States. The FDA does not have to follow the recommendations of its advisory panels, but it typically does.

Epidiolex is manufactured by the British firm GW Pharmaceuticals, which funded the latest clinical trial.

“This is a historic moment in medicine,” Devinsky said. “Hopefully, the FDA will approve this medication in their June meeting and cannabidiol will be available for children and adults with these two rare epilepsies.”

See also  Wholesale CBD Oil For Pets

Although CBD oil has become a trendy cure-all, treatment of epilepsy is the only use that has garnered significant scientific evidence supporting its usefulness.

This latest study is the first to compare two different doses of Epidiolex head-to-head and against an inactive placebo, Devinsky said.

A total of 225 patients suffering from Lennox-Gastaut syndrome were divided into three groups. Those taking 20 mg of Epidiolex a day had 42 percent fewer seizures, on average, compared with 37 percent fewer seizures in the group taking 10 mg of the drug, and a 17 percent reduction in the placebo group.

But while the 20-mg dose was slightly more effective, it was not the first choice of parents, Devinsky said.

“When parents were asked to rate how their children did best, they actually had a slight preference for the 10-mg dose without knowing what it was,” he added.

That’s because these kids did not experience as many side effects from the cannabidiol, which can include tiredness, decreased appetite, diarrhea and signs of possible liver damage, Devinsky explained.

“They got the vast majority of the benefits with fewer of the side effects,” he said.

The study also showed that Epidiolex is a safe treatment, with only seven patients dropping out of the trial due to side effects — six from the 20-mg group and one from the 10-mg group.

“Compared to other drugs used to treat epilepsy, I think Epidiolex, which is 99-percent pure cannabidiol, has a better side-effect profile than many of the available drugs,” Devinsky said.

According to Dr. Angel Hernandez, of the Helen DeVos Children’s Hospital in Grand Rapids, Mich., these results prove that pharmaceutical-grade CBD helps suppress seizures and “increases our options to treat many of these patients with very, very difficult-to-control epilepsies.” Hernandez is division chief of neuroscience at the hospital.

“We’re talking about types of epilepsy that are extremely difficult to treat with medication,” he said. “Most of these children and adults do not respond to normal pharmacological treatment.”

No one is exactly sure why CBD has this beneficial effect, both Devinsky and Hernandez said. It appears to work on receptors that alter brain chemistry in a way that reduces the chances of a seizure.

The doctors noted that these effects were seen in patients taking a highly refined form of CBD produced by a drug maker. It’s not known whether patients in states where medical marijuana is legal would see the same effects in CBD oil produced by small companies with no federal oversight.

It’s also not clear whether CBD would help people with more common forms of epilepsy. Devinsky said small clinical trials have so far found no benefit in people with focal epilepsy, where seizures start on one side of the brain.

“I think we need more studies,” Devinsky said. “It’s not been investigated in generalized epilepsy, and I think we need a larger study in focal epilepsy.”

The findings were published online May 17 in the New England Journal of Medicine.

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.